UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

August 1, 2013

Date of Report (Date of earliest event reported)

NU SKIN ENTERPRISES, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-12421

87-0565309

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification Number)

75 West Center Street

Provo, UT 84601

(Address of principal executive offices and zip code)

(801) 345-1000

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Item 2.02 Results of Operations and Financial Condition.

On August 1, 2013, Nu Skin Enterprises, Inc. (the "Company") issued a press release announcing its financial results for the second quarter and six-month period ended June 30, 2013, and certain other information. A copy of the Company's press release is attached as Exhibit 99.1 to this report and incorporated by reference.

The information furnished pursuant to this Item 2.02 and the exhibit hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

- (d) Exhibit.
 - 99.1 Nu Skin Enterprises' press release dated August 1, 2013, regarding financial results for the second quarter and sixmonth period ended June 30, 2013.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NU SKIN ENTERPRISES, INC.

(Registrant)

<u>/s/ Ritch Wood</u> Ritch Wood Chief Financial Officer

Date: August 1, 2013

<u>Exhibit No.</u>

Exhibit Description

99.1 Nu Skin Enterprises' press release dated August 1, 2013, regarding financial results for the second quarter and sixmonth period ended June 30, 2013.



FOR IMMEDIATE RELEASE

CONTACTS: Investors — Scott Pond (801) 345-2657, <u>spond@nuskin.com</u> Media — Kara Schneck (801) 345-2116, <u>kschneck@nuskin.com</u>

NU SKIN ENTERPRISES REPORTS RECORD SECOND-QUARTER RESULTS

Company raises annual sales forecast \$90 million

PROVO, Utah — Aug. 1, 2013 — Nu Skin Enterprises, Inc. (NYSE: NUS) today announced record second-quarter results with revenue of \$682.9 million, a 15 percent increase over the prior-year period. Revenue for the quarter was negatively impacted 3 percent by foreign currency fluctuations. Quarterly earnings per share increased 30 percent to \$1.22 from \$0.94 in the prior year.

"We are extremely pleased with second-quarter results that reflect the strong momentum of the business," said Truman Hunt, president and chief executive officer. "We are particularly pleased with these results given the record regional ageLOC product launches in the prior-year period. Additionally, we generated continued growth of both our consumer and sales leader base, reflected in 32 percent growth in actives and 23 percent growth in sales leaders. Overall, we saw healthy trends throughout the global business, particularly in the Greater China, North Asia and Americas regions."

"Sales force enthusiasm for the introduction of our ageLOC TR90 weight management system bodes well for a strong second half of the year. We plan to begin the limited-time offer of ageLOC TR90 in September and believe this new product provides an ideal vehicle for us to increase our presence in the growing weight management category."

Nu Skin Enterprises, Inc. Aug. 1, 2013 Page 2

Regional Results

Greater China. In Greater China, second-quarter revenue increased 35 percent to \$269.1 million, compared to \$199.7 million in the prior year, which included approximately \$100 million in product launch revenue. The region's results were negatively impacted 3 percent by foreign currency fluctuations. The sales leader count in the region improved 51 percent, while the number of actives increased 121 percent compared to the prior year.

North Asia. Second-quarter revenue in North Asia was \$196.8 million, compared to \$177.7 million for the same period of 2012. The region's results were negatively impacted 12 percent by foreign currency fluctuations. Japan local-currency revenue improved 5 percent and South Korea generated local-currency revenue growth of 54 percent. The number of sales leaders in the region was up 21 percent while the number of actives improved 15 percent.

South Asia/Pacific. Revenue in South Asia/Pacific was \$85.9 million, a 13 percent decline compared to the prior year. Revenue in the prior year included approximately \$40 million in product launch sales. Results were not notably impacted by foreign currency fluctuations. The region's second-quarter sales leaders decreased 20 percent while actives increased 16 percent compared to the same period in 2012.

Americas. Revenue in the Americas improved 17 percent to \$84.3 million, compared to \$71.8 million in the prior-year period. The region's results were negatively impacted 5 percent by foreign currency fluctuations. The number of sales leaders in the region improved 16 percent while the number of actives increased 3 percent compared to the prior year.

EMEA. Revenue in the EMEA region was \$46.8 million, a 2 percent improvement over the prior-year period. The region's results were positively impacted 1 percent by foreign currency fluctuations. Sales leaders decreased 3 percent, while actives increased 4 percent compared to the prior year.

Nu Skin Enterprises, Inc. Aug. 1, 2013 Page 3

Operational Performance

The company's operating margin was 16.8 percent for the quarter, compared to 16.5 percent, while gross margin was 83.7 percent, compared to 83.9 percent in the prior year. Selling expenses, as a percent of revenue, were 45.2 percent in the second quarter. General and administrative expenses, as a percent of revenue, improved to 21.7 percent from 22.3 percent in the prior-year period. Other income (expense) reflected an expense of \$1.1 million compared to a \$3.4 million expense in the prior year.

The company's income tax rate for the quarter was 34.4 percent compared to 36.1 percent in the prior-year period. The company's cash and short-term investment position at the end of the quarter was \$411.4 million. Dividend payments were \$17.6 million.

Outlook

"As we look to the back half of the year, we are ramping up for what we expect to be our largest-ever product launch," said Hunt. "Given the growth momentum of the business, we are again increasing the sales forecast for the remainder of the year. We expect the upcoming launch of ageLOC TR90 and the strength of the business in several key markets will lead to another record year as annual revenue will approach the \$3 billion mark," Hunt concluded.

"Given the significant growth in our actives, we are raising our annual sales guidance by \$90 million to \$2.91 to \$2.95 billion," said Ritch Wood, chief financial officer. We now expect earnings per share to be \$5.05 to \$5.15 and continue to project a negative 5 percent foreign currency impact to annual revenue."

"In the third quarter, we will introduce ageLOC TR90 for a limited time in the Greater China region and much of South Asia in advance of our global convention," continued Wood. "With these ageLOC TR90 sales, we anticipate third-quarter revenue to be between \$790 and \$810 million, with a negative currency impact to revenue of 6 to 7 percent. We anticipate earnings per share to be \$1.63 to \$1.70 for the quarter," concluded Wood.

Nu Skin Enterprises, Inc. Aug. 1, 2013 Page 4

The company's management will host a webcast with the investment community on Aug. 1, 2013, at 11 a.m. EDT. Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on Nu Skin Enterprises' website, <u>http://ir.nuskin.com</u>. An archive of the webcast will be available at this same URL through Aug. 16, 2013.

About Nu Skin Enterprises, Inc.

Nu Skin Enterprises, Inc. demonstrates its tradition of innovation through its comprehensive anti-aging product portfolio, independent business opportunity and corporate social responsibility initiatives. The company's scientific leadership in both skin care and nutrition has established Nu Skin as a premier anti-aging company. The company's anti-aging products feature the new ageLOC[®] suite of products including the ageLOC[®] R² nutritional supplement, ageLOC[®] Galvanic Spa System and ageLOC[®] Galvanic Body Spa[™], as well as the ageLOC[®] Transformation daily skin care system. A global direct selling company, Nu Skin operates in 53 markets worldwide and is traded on the New York Stock Exchange under the symbol "NUS." More information is available at http://www.nuskin.com.

Please Note: This press release, particularly the "Outlook" section, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the company's performance, initiatives, strategies, new product introductions and growth in the company's markets, including mainland China; statements of projections regarding revenue, earnings per share, foreign currency impact and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "project," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "could," "may," "might," the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

- any failure of current or planned initiatives or products to generate interest among distributors and customers and generate sponsoring and selling activities on a sustained basis;
- risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support our planned initiatives or launch strategies, including possible ingredient supply limitations;
- · challenging economic conditions globally;
- risk of foreign currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;
- risks associated with general inquiries and complaints to consumer protection agencies in Japan regarding the activities of some distributors;
- · risks associated with our ability to manage rapid growth, particularly in our greater China region;
- regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit the company's ability to import or continue selling a product in a market if it is determined to be a medical device or if it is unable to register the product in a timely manner under applicable regulatory requirements;
- continued regulatory scrutiny and investigations in Mainland China, which have from time to time in the past, and could in the future, negatively impact the company's business, including the interruption of sales activities in stores, loss of licenses, and the imposition of fines;
- adverse publicity related to the company's business, products, industry or any legal actions or complaints by distributors or others;
 any prospective or retrospective increases in duties on the company's products imported into the company's markets outside of the
- United States and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and
- · continued competitive pressures in the company's markets.

The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

NU SKIN ENTERPRISES, INC. Consolidated Statements of Income (Unaudited) For the Second Quarters Ended June 30, 2013 and 2012 (in thousands, except per share amounts)

	2013		2012	
Revenue: Greater China North Asia South Asia/Pacific Americas EMEA	\$	269,146 196,757 85,916 84,289 46,819	\$	199,728 177,695 98,344 71,766 45,702
Total revenue		682,927		593,235
Cost of sales		111,273		95,584
Gross profit		571,654		497,651
Operating expenses: Selling expenses General and administrative expenses Total operating expenses		308,769 148,302 457,071		267,363 132,376 399,739
Operating income		114,583		97,912
Other income (expense), net Income before provision for income taxes Provision for income taxes Net income	\$	(1,187) 113,396 38,961	¢	(3,369) 94,543 34,136
	<u>Ф</u>	74,435	\$	60,407
Net income per share: Basic Diluted	\$ \$	1.27 1.22	\$ \$	0.98 0.94
Weighted average common shares outstanding: Basic Diluted		58,620 61,121		61,706 64,230

NU SKIN ENTERPRISES, INC. Consolidated Statements of Income (Unaudited) For the Six Month Periods Ended June 30, 2013 and 2012 (in thousands, except per share amounts)

		2013		2012
Revenue: Greater China North Asia South Asia/Pacific Americas EMEA	\$	444,852 384,950 153,158 160,830 89,231	\$	292,339 359,895 175,665 138,106 89,232
Total revenue		1,233,021		1,055,237
Cost of sales		201,318		171,340
Gross profit		1,031,703		883,897
Operating expenses: Selling expenses General and administrative expenses Total operating expenses		550,652 283,809 834,461		469,898 244,424 714,322
Operating income		197,242		169,575
Other income (expense), net Income before provision for income taxes Provision for income taxes		(1,075) 196,167 67,450	_	266 169,841 61,605
Net income	\$	128,717	\$	108,236
Net income per share: Basic Diluted	\$ \$	2.20 2.11	\$ \$	1.75 1.67
Weighted average common shares outstanding: Basic Diluted		58,487 60,882		62,016 64,773

NU SKIN ENTERPRISES, INC. Consolidated Balance Sheets (Unaudited) (in thousands)

	June 30, 2013		December 31, 2012		
ASSETS					
Current assets:					
Cash and cash equivalents	\$	402,678	\$	320,025	
Current investments		8,754		13,378	
Accounts receivable		59,043		36,850	
Inventories, net		178,183		135,874	
Prepaid expenses and other		117,138		93,276	
		765,796		599,403	
Property and equipment, net		304,619		229,787	
Goodwill		112,446		112,446	
Other intangible assets, net		87,644		92,518	
Other assets		122,202		118,753	
Total assets	\$	1,392,707	\$	1,152,907	
LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:					
Accounts payable	\$	48,954	\$	47,882	
Accrued expenses		355,215		233,202	
Current portion of long-term debt		69,461		39,019	
		473,630		320,103	
Long-term debt		128,664		154,963	
Other liabilities		98,326		87,229	
Total liabilities		700,620		562,295	
Stockholders' equity:					
Class A common stock		91		91	
Additional paid-in capital		332,588		317,293	
Treasury stock, at cost		(718,800)		(714,853)	
Accumulated other comprehensive loss		(55,272)		(51,822)	
Retained earnings		1,133,480		1,039,903	
		692,087		590,612	
Total liabilities and stockholders' equity	\$	1,392,707	\$	1,152,907	

NU SKIN ENTERPRISES, INC. Actives/Sales Leaders Statistics

	As of June	As of June 30, 2013		As of June 30, 2012		% Increase (Decrease)		
	Actives	Sales Leaders	Actives	Sales Leaders	Actives	Sales Leaders		
Greater China North Asia South Asia/Pacific	376,000 389,000 114,000	30,455 17,372 7,120	170,000 337,000 99,000	20,182 14,370 8,856	121.2% 15.4% 15.2%	50.9% 20.9% (19.6%)		
Americas EMEA	176,000 124,000	6,954 4,484	170,000 119,000	5,994 4,626	3.5% 4.2%	16.0% (3.1%)		
Total	1,179,000	66,385	895,000	54,028	31.7%	22.9%		

"Actives" are persons who purchased products directly from the company during the previous three months.

"Sales Leaders" are persons who have completed and who maintain specified sales requirements. Sales Leaders include our independent distributors who have completed and who maintain specified sales requirements, and our sales employees and contractual sales promoters in China, who have completed certain qualification requirements.

###